David Sherris is CEO and shareholder of Paloma Pharmaceuticals.
Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood–Brain Barrier without restriction by ABCB1 and ABCG2
Version of Record online: 1 APR 2013
Copyright © 2013 UICC
International Journal of Cancer
Volume 133, Issue 5, pages 1222–1233, 1 September 2013
How to Cite
Lin, F., Buil, L., Sherris, D., Beijnen, J. H. and van Tellingen, O. (2013), Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood–Brain Barrier without restriction by ABCB1 and ABCG2. Int. J. Cancer, 133: 1222–1233. doi: 10.1002/ijc.28126
- Issue online: 18 JUN 2013
- Version of Record online: 1 APR 2013
- Accepted manuscript online: 22 FEB 2013 04:31AM EST
- Manuscript Accepted: 24 JAN 2013
- Manuscript Received: 8 JUL 2012
- StopHersentumoren to OvT
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.